These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3700686)

  • 1. Generic equivalents: issues and concerns.
    Lamy PP
    J Clin Pharmacol; 1986; 26(5):309-16. PubMed ID: 3700686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability and bioequivalence.
    Skelly JP
    J Clin Pharmacol; 1976 Oct; 16(10 Pt 2):539-45. PubMed ID: 977792
    [No Abstract]   [Full Text] [Related]  

  • 3. A history of biopharmaceutics in the Food and Drug Administration 1968-1993.
    Skelly JP
    AAPS J; 2010 Mar; 12(1):44-50. PubMed ID: 19936940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generic equivalence and non-equivalence of drugs.
    Smith RN
    Lancet; 1972 Sep; 2(7776):528-30. PubMed ID: 4115582
    [No Abstract]   [Full Text] [Related]  

  • 5. Mental health and the elderly: new biopharmaceutic considerations.
    Cabana BE
    Health Aff (Millwood); 1983; 2(3):33-8. PubMed ID: 6654313
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic inequivalence.
    Rheinstein PH
    Drug Saf; 1990; 5 Suppl 1():114-9. PubMed ID: 2182054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug bioequivalence. Recommendations from the Drug Bioequivalence Study Panel to the Office of Technology Assessment, Congress of the United States.
    J Pharmacokinet Biopharm; 1974 Oct; 2(5):433-66. PubMed ID: 4452945
    [No Abstract]   [Full Text] [Related]  

  • 8. Doctors are pivotal to prescription struggle.
    Chapman S
    Leg Aspects Med Pract; 1979 Mar; 7(3):42-4. PubMed ID: 423688
    [No Abstract]   [Full Text] [Related]  

  • 9. Bioavailability and bioequivalence: an FDA regulatory overview.
    Chen ML; Shah V; Patnaik R; Adams W; Hussain A; Conner D; Mehta M; Malinowski H; Lazor J; Huang SM; Hare D; Lesko L; Sporn D; Williams R
    Pharm Res; 2001 Dec; 18(12):1645-50. PubMed ID: 11785681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bioavailability of drug products and bioequivalence requirements (author's transl)].
    Jaminet F
    J Pharm Belg; 1978; 33(3):141-56. PubMed ID: 682101
    [No Abstract]   [Full Text] [Related]  

  • 11. Importance of biopharmaceutics and pharmacokinetics in clinical medicine.
    Cabana BE
    Arzneimittelforschung; 1976; 26(1A):151-8. PubMed ID: 947194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generic drug substitution revisited.
    Strom BL
    N Engl J Med; 1987 Jun; 316(23):1456-62. PubMed ID: 3553952
    [No Abstract]   [Full Text] [Related]  

  • 13. Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.
    Khan MZ; Rausl D; Radosević S; Filić D; Danilovski A; Dumić M; Knezević Z
    J Pharm Pharmacol; 2006 Nov; 58(11):1475-82. PubMed ID: 17132210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development.
    Mehta MU; Uppoor RS; Conner DP; Seo P; Vaidyanathan J; Volpe DA; Stier E; Chilukuri D; Dorantes A; Ghosh T; Mandula H; Raines K; Dhanormchitphong P; Woodcock J; Yu LX
    Mol Pharm; 2017 Dec; 14(12):4334-4338. PubMed ID: 29076742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical therapeutic categories: a contraindication to generic substitution?
    Colaizzi JL; Lowenthal DT
    Clin Ther; 1986; 8(4):370-9. PubMed ID: 3731208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic availability and therapeutic equivalence.
    Arnold JD; Sicé J
    J Clin Pharmacol; 1976 Oct; 16(10 Pt 2):546-9. PubMed ID: 977793
    [No Abstract]   [Full Text] [Related]  

  • 18. Generic drugs and the prescribing physician.
    Nightingale SL; Morrison JC
    JAMA; 1987 Sep; 258(9):1200-4. PubMed ID: 3626003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence of generic thioridazine drug products--the FDA viewpoint.
    Hamrell MR; Martinez MN; Dighe SV; Parkman PD
    Drug Intell Clin Pharm; 1987 Apr; 21(4):362-72. PubMed ID: 3569040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential clinical significance of differences in bioavailability.
    Hosp Formul; 1976 Sep; 11(9):484, 487-8. PubMed ID: 10316482
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.